People searching for "Ozempic nails" have usually noticed brittle tips, color changes, or a nail lifting from its bed. Until recently, doctors had almost no controlled data on whether GLP-1 drugs were linked to nail problems. Earlier evidence was largely anecdotal.
As of October 17, 2026, the day this article was written, EADV announced what it describes as the first controlled GLP-1 nail study. Adults taking GLP-1 drugs reported nail detachment about four times as often as comparable non-users. Still, a survey cannot prove that the medication itself caused those changes.
Around half of the GLP-1 users already had nail issues before starting treatment, and weight loss itself affects nail growth. Meanwhile, U.S. labels for Ozempic, Wegovy, Mounjaro, and Zepbound do not list any nail disorders. Here is what the October 2026 research found, what else makes nails lift, and when to see a doctor.
What the 2026 study found on Ozempic nails and GLP-1s
On October 1, 2026, the European Academy of Dermatology and Venereology (EADV) announced findings from its 2026 Congress in Vienna. Researchers led by Bianca Maria Piraccini surveyed adults with obesity, type 2 diabetes, or both across four countries. Participants lived in the United States, France, Brazil, and Mexico.
The survey compared 575 GLP-1 users with 1,329 comparable adults who had never taken a GLP-1 medication. In that group, 39% of GLP-1 users (about 2 in 5 people) reported nail detachment, versus 9% of controls.
| EADV survey outcome | GLP-1 users (n = 575) | Controls (n = 1,329) |
|---|---|---|
| Any nail disorder | 66% | 53% |
| Nail detachment | 39% | 9% |
| Nail discoloration | 46% | 17% |
That 39% figure measures reported symptoms in this survey sample, not a new user's personal risk on Ozempic. Roughly half of the GLP-1 users reported having nail problems even before they started treatment. The release also pooled GLP-1 medications together rather than separating semaglutide, tirzepatide, or individual doses.
Why the survey cannot prove a direct drug effect
When the researchers adjusted for skin conditions and nutritional deficiencies, several links weakened. Reported nail detachment and discoloration stayed about two to three times as common in the GLP-1 group. Differences also remained significant among participants who lost weight, so neither weight loss alone nor a drug mechanism is proven.
The October 1 release describes conference findings, and no full peer-reviewed paper from the EADV team appeared in PubMed or Crossref searches. Outcomes were self-reported, and the release does not document clinical confirmation. DUCRAY Laboratories (Pierre Fabre Group) provided institutional support.
The team plans follow-up studies with dermatology exams and lab monitoring to see when symptoms start and whether they reverse. Until then, the findings show an association between GLP-1 use and reported nail disorders, without establishing a drug-specific link or causation.
Onycholysis vs. brittle nails during GLP-1 treatment
A lifting nail and ordinary brittleness describe different changes. According to the American Academy of Dermatology (AAD), onycholysis means a nail lifts away from the skin underneath. The lifted part usually looks white, and the whole nail does not necessarily fall off.
Keep that general definition separate from the EADV survey's 39% nail detachment figure. Congress coverage featuring the lead investigator listed onycholysis and nail detachment as separate survey items, and the original questionnaire is unavailable.
Everyday brittleness is different from a lifting nail. In February 2026 GLP-1 guidance, the AAD notes that major weight loss can slow nail growth and cause brittle nails. Significant weight loss may contribute to brittle nails during treatment with semaglutide or tirzepatide, but it does not explain every lifting nail.
Do U.S. labels for Ozempic or Mounjaro list nail problems?
The four U.S. prescribing-information records provide the label comparison below. A full check of the clinical-trial (§6.1) and postmarketing (§6.2) side-effect sections across all four major brands shows no nail disorders. Neither nail detachment, onycholysis, nor brittle nails appears in the Ozempic, Wegovy, Mounjaro, or Zepbound adverse-reaction sections.
| Branded U.S. label | Revised | Nail disorders in §6.1 / §6.2 | Hair entry in §6.1 / §6.2 |
|---|---|---|---|
| Ozempic (semaglutide) | 5/2026 | None named | Alopecia in §6.2 (no frequency) |
| Wegovy (semaglutide) | 6/2026 | None named | Hair loss in §6.1 (3% vs. 1% placebo) |
| Mounjaro (tirzepatide) | 8/2026 | None named | Alopecia in §6.2 (no frequency) |
| Zepbound (tirzepatide) | 8/2026 | None named | Hair loss in §6.1 (4%–5% vs. 1% placebo) |
Absence from a label does not prove that nail changes are impossible. Clinical trials use different methods than symptom surveys, and common-reaction tables often require at least a 5% incidence. An August 2026 Dermatology and Therapy survey of 1,226 telemedicine responses also noted that one-time surveys cannot separate drug effects from weight loss.
In the EADV companion survey, 50% of GLP-1 users reported unusual hair loss versus 34% of controls. A 2026 Laryngoscope cohort study and an October 2026 Acta Diabetologica review discuss weight-loss stress and telogen effluvium (temporary stress-related shedding). Those hair mechanisms are unproven for nails; see our guides on semaglutide hair loss and tirzepatide hair loss.
Other causes of lifting nails and when to see a doctor
Assuming a medication caused a nail change can delay care for a treatable problem. The AAD notes that fungal infections, psoriasis, and injury from manicures or cleaning under the nail commonly make a nail lift. In its thyroid disease checklist, the AAD adds that thyroid conditions can leave nails thick, dry, brittle, or lifted.
Because appearance alone cannot diagnose the cause, the AAD advises having a dermatologist examine any nail that is lifting up. Redness and swelling around a nail can signal an infection, while greenish-black color often points to bacteria. Any new or changing dark streak under a nail also needs a dermatologist's evaluation.
EADV researchers called the reported nail changes frequent and usually benign. They advised patients to consult a doctor or dermatologist rather than stop therapy on their own. Moisturizing cuticles helps routine dryness, while a clinician should guide any lab tests or supplements.
How compounded GLP-1 prescriptions work at Promise
If you are considering a GLP-1 medication, it helps to distinguish branded trial products from compounded preparations. Compounded preparations are different from FDA-approved brands like Ozempic, Wegovy, Mounjaro, and Zepbound. Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy, and the same applies to tirzepatide.
Each medication is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Even so, a licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request and not everyone qualifies. During intake and follow-up visits, the reviewing provider can evaluate your medical history and any nail changes you notice.
